The muscarinic receptor subtype in mouse pancreatic B-cells  by Henquin, J.C. & Nenquin, M.
Volume 236, number 1, 89-92 FEB 06171 August 1988 
The muscarinic receptor subtype in mouse pancreatic B-cells 
J.C. Henquin and M. Nenquin 
Unit6 de Diabktologie et Nutrition, UCL 54.74, University of Louvain, Faculty of Medicine, B-1200 Brussels, Belgium 
Received 16 June 1988 
Isolated mouse islets were used to identify the muscarinic receptor subtype present in pancreatic B-cells. We thus com- 
pared the inhibitory potencies of atropine (non-specific), of pirenzepine (specific for M, receptors) and of compound 
AF-DX 116 (specific for cardiac M receptors) on acetylcholine-induced insulin release, B6Rb+ efflux and *5Ca2+ efflux. 
The three antagonists inhibited all effects of acetylcholine, but EC,, values were markedly different: atropine= 1.5-S nM, 
pirenzepine = 0.61.7 PM and AF-DX 116 = 1.7-l 1 PM. The results did not suggest that the various effects of ACh could 
result from the activation of different subtypes of receptors. It is concluded that muscarinic receptors of pancreatic B-cells 
belong to an M2 subtype distinct from the cardiac Mz receptors. 
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1. INTRODUCTION 
Stimulation of muscarinic receptors (mAChR) 
triggers a broad spectrum of biochemical and 
biophysical events [l]. The diversity of these 
cellular responses may be linked to the existence of 
distinct subtypes of receptors, activating different 
transduction pathways. The first evidence for the 
heterogeneity of mAChR was based on the dif- 
ferential affinity and inhibitory potency displayed 
by the antagonist pirenzepine (PZ) in different 
tissues [2,3]. An Ml subtype, with high affinity for 
PZ, was identified in the central nervous system 
and sympathetic ganglia, whereas an MZ subtype, 
with low affinity for PZ, was found in peripheral 
effector organs. However, a new antagonist, AF- 
DX 116, with a high affinity for MZ receptors of 
the heart and a low affinity for Mz receptors of ex- 
ocrine glands, has led to further subdivision [4-61. 
This pharmacological concept of mAChR 
heterogeneity was amply supported by recent 
molecular cloning studies, which identified no less 
than four distinct mAChR, with very large 
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homologies in man, pig and rat [7-l 11. Expression 
of these receptor subtypes varies between tissues, 
but the links between each subtype and a defined 
pathway of signal transduction are only recently 
beginning to be unravelled [l 11. 
It has long been known that ACh modulates in- 
sulin secretion by activating mAChR of pancreatic 
B-cells [ 12,131. Several mechanisms including ac- 
celeration of phosphoinositide hydrolysis, mo- 
bilization of intracellular calcium and changes 
in several ionic permeabilities of the plasma mem- 
brane are involved, but their precise links and 
relative importance remain under debate [ 13- 181. 
The present study was an attempt to identify the 
mAChR subtype(s) mediating some of these effects 
of ACh in B-cells. We thus compared the ability of 
atropine, PZ and AF-DX 116 to antagonize ACh- 
induced insulin release, “Rb+ efflux and in- 
tracellular Ca2+ mobilization in isolated mouse 
islets. 
2. MATERIALS AND METHODS 
Islets were isolated after collagenase digestion of the pancreas 
of fed female NMRI mice. They were then incubated for 90 min 
at 37°C in a control medium, or in a medium supplemented 
with a trace amount of s6RbC1 or ‘%aCb. For studies of insulin 
release, batches of 3 islets were subsequently incubated for 
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60 min in 1 ml of medium containing the test substances. At the 
end of the incubation, a portion of the medium was ap- 
propriately diluted for measurement of immunoreactive insulin, 
with rat insulin as standard. The techniques and the dynamic 
system of perifusion used to monitor the efflux of *‘Rb+ (tracer 
for K+) or “Ca” from preloaded islets have been described in 
detail [17,19]. During the experiments of ‘%a’+ efflux, a por- 
tion of each effluent fraction was also saved for measurement 
of insulin. 
The medium used was a bicarbonate-buffered solution [14] 
containing 10 mM glucose in all experiments. Acetylcholine 
chloride was obtained from Sigma (St. Louis, USA), atropine 
sulfate from Merck (Darmstadt, FRG), and the radioisotopes 
from the Radiochemical Center (Amersham, England). 
Pirenzepine and AF-DX 116 (1 I-[[2-[(diethylamino)methyl]-l- 
piperidinyllacetyll-5,l I-dihydro-6H-pyrido[2,3-b1[1,4]benzodi- 
azepine-6-one) were kindly provided by Thomae GmbH 
(Biberach, FRG). 
Depending on the phenomenon studied, each antagonist was 
tested at 3-5 concentrations in the presence of one concentra- 
tion of ACh. The control response to ACh alone and the test 
responses in the presence of all concentrations of one antagonist 
were obtained in each experiment of incubation aimed at 
measuring insulin release. For technical reasons, however, ef- 
flux experiments could not always compare the control response 
to ACh alone and the test responses in the presence of all con- 
centrations of one antagonist with the same preparation of 
islets. After subtraction of basal responses (without ACh), test 
responses in the presence of an antagonist were expressed as a 
percentage of the control response with ACh alone. To 
calculate the potency of the antagonists, the average 
concentration-response curves were first linearized by the least 
square method after probit transformation of the percentages 
[20]. The concentration producing 50% inhibition of ACh ef- 
fects (E&) was obtained from the regression plot. 
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3. RESULTS 
The control effects of ACh are shown in fig.1. 
At the concentration of 1 PM, ACh produced a 
ten-fold increase in insulin release by islets in- 
cubated in a medium containing 10 mM glucose 
and 2.5 mM Ca2+. The same concentration of 
ACh also caused a marked and sustained accelera- 
tion of 86Rb+ efflux from islets perifused with a 
Ca2+-free medium (fig.lB). At the higher concen- 
tration of 100 PM, ACh triggered a prominent but 
transient peak of 45Ca2+ efflux from islets peri- 
fused with a Ca2+-free medium. This peak, which 
therefore reflects intracellular Ca2+ mobilization, 
was accompanied by a short-lived release of insulin 
(fig.lD). The strong inhibitory effect of 10 nM 
atropine attests to the muscarinic nature of all 
these effects of ACh. 
The 3 muscarinic antagonists caused a dose- 
dependent inhibition of ACh-induced insulin 
release, “Rb+ efflux and 45Ca2+ efflux (fig.2). 
However, their potencies were widely different. 
Comparison of ECK, values shows that PZ was 
about 240-400 times less potent than atropine, and 
that AF-DX 116 was 3-7 times less potent than PZ 
(table 1). EGO values could not be reliably 
estimated for the inhibition of the peak of insulin 
release triggered by ACh in the absence of Ca2+ 
(fig. 1D) because it was already markedly decreased 
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Fig.1. Inhibition by 10 nM atropine of various effects of ACh in mouse islets incubated in the presence of 2.5 mM Ca2+ (A) or 
perifused in the absence of Ca*+ (B-D). The concentration of glucose was 10 mM in all experiments. In A, ACh, with or without 
atropine, was present during the whole incubation. In B-D, ACh was added as indicated by the arrows whereas atropine, when tested, 
was present during the whole experiment. Values are means f SE for 26-74 batches of islets (A), and for 4 test (0) and 8 control (0) 
experiments of efflux (B-D). Panel D illustrates the changes in insulin release measured during the experiments of 45Ca2+ efflux (C). 
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Fig.2. Concentration dependence of the inhibition of ACh 
effects by atropine, PZ and AF-DX 116. Results are expressed 
as a percentage of the control response to ACh alone, above 
basal values without ACh. These control responses are shown 
in fig. 1. For efflux experiments, basal values correspond to the 
average rate just before addition of ACh (36-40 min or 
26-30 min); test values correspond to the average rates between 
42 and 60 min (“Rb+ efflux) or between 32 and 36 min (%a*+ 
efflux). Values are means + SE (when larger than the symbol) 
for 24-26 batches of islets from 4 separate experiments (insulin 
release) or 4 experiments of efflux. 
by the lowest concentrations of the antagonists. 
Compared to control values, this peak amounted 
to only 18 f 3% with 2.5 nM atropine, 3 1 + 4% 
with 250 nM PZ and 52 f 7% with 2.5 PM AF-DX 
116. 
EC50 values for atropine, PZ and AF-DX 116 antagonism of 
ACh effects in mouse islets 
Atropine AF-DX 116 
(nM) :iG (SW 
Insulin release 1.45 0.55 1.65 
86Rb+ efflux 4.20 1.70 10.7 
%a*+ efflux 5.00 1.20 8.15 
Values were calculated from the data of fig.2, as described in 
section 2 
At the highest concentrations tested, atropine 
(lOrM), PZ (100yM) and AF-DX 116 (1OOpM) 
had no effect on insulin release, 86Rb+ efflux or 
45Ca2+ efflux in the absence of ACh (not shown). 
4. DISCUSSION 
The nature of the mAChR subtype present in 
pancreatic B-cells was addressed in only one 
previous study [21]. From experiments using only 
two concentrations of antagonists, it was suggested 
that about 300 times more PZ than atropine is 
needed to inhibit carbachol-induced insulin release 
from the perfused rat pancreas. This estimation 
agrees with our finding of an EC50 ratio of 380. A 
similar low sensitivity to PZ (EC50 in thepM range) 
was also observed here when its effects on *‘Rb+ 
and 45Ca2+ efflux were tested. One may thus 
reasonably conclude that B-cells do not possess 
mAChR of the Ml subtype. Since the cardioselec- 
tive MZ antagonist AF-DX 116 was even less potent 
than PZ, it appears that mAChR of B-cells, like 
those of exocrine glands [5,6], differ from the car- 
diac MZ subtype. 
There are no direct arguments to identify these 
glandular M2 mAChR of B-cells as MS or M4 
receptors. However, the M3 subtype appears to be 
expressed mainly in tissues where ACh causes in- 
hibition of adenylate cyclase [l 11, and this is not 
the case in B-cells [13]. On the other hand, the M4 
subtype is expressed in the exocrine pancreas [111. 
In the latter tissue [22], as in B-cells [13-181, 
muscarinic agonists cause phosphoinositide 
hydrolysis, Ca2+ mobilization, changes in several 
ionic fluxes and secretion. The glandular Mz sub- 
type could turn out to be an M4 mAChR. 
Several, but not necessarily all effects brought 
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about by ACh in B-cells are interconnected 
[17,18]. Slight differences in the potencies of the 
antagonists on ACh-induced insulin release and on 
86Rb+ or 45Ca2+ efflux were noted. However, these 
differences are too small to suggest involvement of 
distinct mAChR. They are more likely to be due to 
distinct experimental conditions (e.g. incubations 
in the presence of Cazf and perifusions in the 
absence of Ca’+) in particular since the EC50 
values of the non-specific antagonist atropine were 
similarly affected. Even the high sensitivity of the 
peak of insulin release induced by ACh in the 
absence of Ca2+ is easily explained. This peak is 
due to Ca2+ mobilization (peak of 45Ca2+) by 
inositol trisphosphate. However, concentration- 
dependence studies have shown that the relation- 
ship between insulin release and the magnitude of 
Ca2+ mobilization is non-linear [18]. A small 
decrease in mobilization, as that produced by the 
lowest concentration of antagonists, is sufficient to 
cause a marked reduction in release. The presence 
of only one type of mAChR in B-cells would not 
necessarily imply that ACh triggers one single 
primary response, which, in turn, activates secon- 
dary responses in parallel or in sequence. Indeed, 
evidence has been obtained that a single mAChR 
subtype is able to mediate several biochemical 
responses [23]. 
Acknowledgements: This work was supported by grant 
3.454686 from the FRSM, Brussels. J.C.H. is ‘Maitre de 
Recherches’ of the FNRS, Brussels. We thank M. Gerard for 
skilled assistance, and Dr A. Zimmer for providing PZ and AF- 
DX 116. 
REFERENCES 
Ill Nathanson, N.M. (1987) Annu. Rev. Neurosci. 10, 
195-236. 
[2] Hammer, R., Berrie, C.P., Birdsall, W.J.H., Burgen, 
A.S.V. and Hulme, E.C. (1980) Nature 283, 90-92. 
[3] Watson, M., Yamamura, HI. and Roeske, W.R. (1983) 
Life Sci. 32, 3001-3011. 
[4] Hammer, R., Giraldo, E., Schiavi, G.B., Monferini, E. 
and Ladinsky, H. (1986) Life Sci. 38, 1653-1662. 
[5] Giachetti, A., Micheletti, R. and Montagna, E. (1986) 
Life Sci. 38, 1663-1672. 
[6] Korc, M., Ackerman, M.S. and Roeske, W.R. (1987) J. 
Pharmacol. Exp. Ther. 240, 118-122. 
[7] Kubo, T., Maeda, A., Sugimoto, K., Akiba, I., Mikami, 
A., Takahashi, H., Haga, T., Haga, K., Ichiyama, A., 
Kangawa, K., Matsuo, H., Hirose, T. and Numa, S. 
(1986) FEBS Lett. 209, 367-372. 
[8] Peraha, E.G., Winslow, J.W., Peterson, G.L., Smith, 
D.H., Ashkenazi, A., Ramachandran, J., Schimerlik, 
MI. and Capon, D.J. (1987) Science 236, 600-605. 
[9] Bonner, T.I., Buckley, N.J., Young, AC. and Brann, 
M.R. (1987) Science 237, 527-532. 
[lo] Gocayne, J., Robinson, D.A., Fitzgerald, M.G., Chung, 
F.Z., Kerlavage, A.R., Lentes, K.U., Lai, J., Wang, 
C.D., Fraser, C.M. and Venter, J.C. (1987) Proc. Natl. 
Acad. Sci. USA 84, 8296-8300. 
[ll] Peraha, E.G., Ashkenazi, A., Winslow, J.W., Smith, 
D.H., Ramachandran, J. and Capon, D.J. (1987) EMBO 
J. 6, 3923-3930. 
[12] Miller, R.E. (1981) Endocrine Rev. 2, 471-494. 
[13] Malaisse, W.J. (1986) Diabetes/Metabolism Rev. 2, 
243-259. 
[14] Nenquin, M., Awouters, P., Mathot, F. and Henquin, 
J.C. (1984) FEBS Lett. 176, 457-461. 
[15] Morgan, N.G., Rumford, G.M. and Montague, W. 
(1985) Biochem. J. 228, 713-718. 
[16] Wollheim, C.B. and Biden, T.J. (1986) J. Biol. Chem. 
261, 8314-8319. 
[17] Henquin, J.C., Garcia, M.C., Bozem, M., Hermans, 
M.P. and Nenquin, M. (1988) Endocrinology 122, 
2134-2142. 
[18] Garcia, M.C., Hermans, M.P. and Henquin, J.C. (1988) 
Biochem. J. 254, in press. 
[19] Henquin, J.C. (1979) Nature 280, 66-68. 
[20] Goldstein, A., Aronow, L. and Kalman, S.M. (1974) 
Principles of Drug Action: The Basis of Pharmacology, 
pp.l-854, John Wiley & Sons, New York. 
[21] Otsuki, M., Nakamura, T., Okabayashi, Y., Oka, T., 
Fujii, M. and Baba, S. (1985) Gastroenterology 89, 
408-414. 
[22] Petersen, O.H. (1982) Biochim. Biophys. Acta 694, 
163-184. 
[23] Ashkenazi, A., Winslow, J.W., Peralta, E.G., Peterson, 
G.L., Schimerlik, M.I., Capon, D. J. and Ramachandran, 
J. (1987) Science 238, 672-675. 
92 
